Peptide Comparison
MK-677 vs GHRP-2
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
MK-677 has stronger documented evidence (Phase 3 (not approved)) than GHRP-2 (Japan-Approved Diagnostic) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. GHRP-2 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: water retention. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| MK-677 | GHRP-2 | |
|---|---|---|
| Class | Oral non-peptide ghrelin receptor agonist | GHRP; ghrelin receptor agonist |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine | GHS-R1a agonist; strong GH release |
| Route | Oral | SC / Intranasal |
| Half-life | ~24 hrs | ~15-30 min |
| Dosage (research) | 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) | 100-300 mcg SC 1-3x daily |
| Evidence tier | Phase 3 (not approved) | Japan-Approved Diagnostic |
| Research depth | 120 indexed | 148 indexed |
| Availability | Research Chemical | Research |
| Reported risks | Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) | Cortisol/prolactin increase; hunger; water retention |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick MK-677 or GHRP-2?
MK-677 has stronger documented evidence (Phase 3 (not approved)) than GHRP-2 (Japan-Approved Diagnostic) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. GHRP-2 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between MK-677 and GHRP-2?
MK-677 is classed as Oral non-peptide ghrelin receptor agonist; GHRP-2 is classed as GHRP; ghrelin receptor agonist. Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; GHRP-2, GHS-R1a agonist; strong GH release. Reported half-life: MK-677, ~24 hrs; GHRP-2, ~15-30 min. Routes in published studies: MK-677, Oral; GHRP-2, SC / Intranasal.
Which has stronger evidence, MK-677 or GHRP-2?
MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies. GHRP-2 is graded Japan-Approved Diagnostic, with 1 cited source on its reference page and 148 indexed studies.
Which is more accessible, MK-677 or GHRP-2?
Neither MK-677 nor GHRP-2 is an FDA-approved drug. Catalog status: MK-677, Research Chemical; GHRP-2, Research. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022). FDA lists GHRP-2 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are MK-677 and GHRP-2 ever combined?
MK-677 and GHRP-2 appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…